Salma Health has officially emerged from stealth with $80 million in Series A funding to launch an integrated brain health company designed to unify diagnostics, rapid-acting treatments, and coordinated care under one roof. The round was co-led by Mubadala Capital and ARCH Venture Partners, with participation from Lingotto Horizon and Averin Capital.
Founded to address what it describes as a fragmented and siloed brain healthcare system, Salma Health is building and operating centers of excellence focused on psychiatric, neurological, and neuropsychiatric conditions. More than one-third of Americans experience a brain health condition each year, yet care often spans disconnected specialties such as psychiatry, neurology, psychology, and crisis services. The company aims to consolidate those services into a continuous, technology-enabled care pathway.
Salma Health’s model is structured around three pillars: specially equipped clinics delivering in-person care augmented by telehealth; clinical research capabilities supporting pharmaceutical and medical device trials; and a proprietary AI-driven technology platform powering what it calls Brain Health OS. The platform integrates clinical knowledge, operational coordination, and generative AI to enhance diagnostics, decision support, and care coordination.
The clinics provide advanced therapeutics and intensive programs across a full spectrum of psychiatric and neurological services, including conventional and accelerated transcranial magnetic stimulation, SAINT neuromodulation protocols, esketamine therapy, psychotherapy, and pharmacotherapy. Treatment plans are developed through detailed clinical assessments and delivered by specialized teams focused on personalization and safety.
Beyond care delivery, Salma Health is building a HIPAA-compliant research sandbox designed to partner with pharmaceutical and medical device companies. Patients undergo deep profiling across demographic, neural, physiological, and digital markers, contributing to a comprehensive dataset intended to support predictive care models, early relapse detection, and real-world evidence generation. The company plans to publish outcomes data and contribute to clinical guideline development in partnership with healthcare systems, academic institutions, and regulators.
Salma Health has opened locations in San Diego, Orange County, Fremont, and Berkeley, with additional U.S. expansion planned. The Orange County clinic has been named the Salma Health Nolan Williams Clinic in honor of Dr. Nolan Williams, a founding team member and Director of the Stanford Brain Stimulation Lab, who co-developed the FDA-cleared SAINT neuromodulation system. All SAINT treatment rooms across Salma Health locations will bear his name.
The founding team includes Alaa Halawa, Ayman AlAbdallah, Brandon Bentzley, MD, PhD, Emily Phillips-Bru, and Zeena Ojjeh. The company’s long-term vision is to build a national center of excellence for precision brain health.
KEY QUOTES
“Brain health conditions are deeply complex, yet for decades we’ve just treated them with trial and error. Every member of our team has seen patients struggle through a fragmented system. Salma Health is designed to change that. We’re creating a continuous, integrated care pathway, powered by leading clinicians, advanced science and breakthrough therapeutics. To achieve this, we are building a digital and AI-driven foundation to personalize diagnosis, track outcomes and match each patient to the right care at the right time.”
Alaa Halawa, CEO of Salma Health and Head of Healthcare at Mubadala Capital
“Conventional neurological, psychiatric and behavioral care is designed around first-line treatments, but that approach often leaves patients behind. We’re combining the most advanced therapeutic interventions and integrated clinical protocols to move beyond symptom management and toward true recovery. Our goal isn’t incremental progress; it’s to redefine what’s possible in brain healthcare.”
Brandon Bentzley, MD, PhD, Chief Medical Officer at Salma Health and Co-Developer of the FDA-Cleared SAINT Neuromodulation System
“Our healthcare strategy at Mubadala Capital is focused on building enduring platforms that support patients through every stage of care. Brain health is one of the most important areas in need of that transformation. Salma Health’s integrated model, uniting specialized clinical delivery, advanced technology and research infrastructure, represents the coordinated system this field has long lacked. It is exactly the kind of patient-centered, complex opportunity we aim to invest in.”
Hani Barhoush, CEO of Mubadala Capital
“What excites us about Salma Health is its ability to deliver measurable results while simultaneously advancing the field. By taking a comprehensive, data-driven approach to brain health, the Salma Health team is not just better addressing individual patients; they’re massively improving our understanding of brain conditions. This represents the integral change our healthcare system desperately needs.”
Paul Berns, Managing Director at ARCH Venture Partners
